Christina Jamieson, PhD
Dr. Jamieson is the principal basic sciences researcher in Urologic Oncology. She investigates the causes of bone metastasis to offer hope to patients with advanced, castration resistant prostate cancer.
Most advanced cases of prostate cancer metastasize to the bone, where the prostate tumor fluorishes and also stimulates formation of painful, debilitizing bone tumors. Most therapies usually fail once the cancer advances to this stage, and the patient's condition rapidly declines.
Dr. Jamieson’s team is using gene profiling of bone tissue and subcutaneous tissue that have both been incubated with cancerous prostate tissue to identify genes that are specifically associated with cancer proliferation in bone. There is potential for targeting those genes or their products with drug therapies that would potentially slow down or reverse tumor growth in the bones, or even prevent bone metastasis in the first place. This kind of therapy is urgently needed for patients with advanced prostate cancer that cannot be effectively treated with other therapies.
In November 2013, Dr. Jamieson was honored to receive a significant three-year grant in the amount of $450,000 from The Leo and Anne Albert Charitable Trust to support her research on new patient-derived models of bone metastatic prostate cancer.
Woo JR, Liss MA, Muldong MT, Palazzi K, Strasner A, Ammirante M, Varki N, Shabaik A, Howell S, Kane CJ, Karin M, Jamieson CA. Tumor infiltrating B-cells are increased in prostate cancer tissue. J Transl Med. 2014 Jan 30;12(1):30. [Epub ahead of print] PMID: 24475900
Goff DJ, Recart AC, Sadarangani A, Chun HJ, Barrett CL, Krajewska M, Leu H, Low-Marchelli J, Ma W, Shih AY, Wei J, Zhai D, Geron I, Pu M, Bao L, Chuang R, Balaian L, Gotlib J, Minden M, Martinelli G, Rusert J, Dao KH, Shazand K, Wentworth P, Smith KM, Jamieson CA, Morris SR, Messer K, Goldstein LS, Hudson TJ, Marra M, Frazer KA, Pellecchia M, Reed JC, Jamieson CH. A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell. 2013 Mar 7;12(3):316-28. PMID: 23333150
Ma W, Gutierrez A, Goff DJ, Geron I, Sadarangani A, Jamieson CA, Court AC, Shih AY, Jiang Q, Wu CC, Li K, Smith KM, Crews LA, Gibson NW, Deichaite I, Morris SR, Wei P, Carson DA, Look AT, Jamieson CH. NOTCH1 Signaling Promotes Human T-Cell Acute Lymphoblastic Leukemia Initiating Cell Regeneration in Supportive Niches. PLoS One. 2012; 7(6):e39725. PMID: 22768113
Raheem O, Kulidjian AA, Wu C, Jeong YB, Yamaguchi T, Smith KM, Goff D, Leu H, Morris SR, Cacalano NA, Masuda K, Jamieson CH, Kane CJ, Jamieson CA. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. J Transl Med. 2011 Oct 28;9:185. PMID: 22035283
Belanto JJ, Diaz-Perez SV, Magyar CE, Maxwell MM, Yilmaz Y, Topp K, Boso G, Jamieson CH, Cacalano NA, Jamieson CAM. Dexamethasone induces dysferlin in myoblasts and enhances their myogenic differentiation. Neuromuscul Disord. 2010;20(2):111-121.
Peng L, Wu TT, Tchieu JH, Feng J, Brown JH, Feng J, Li X, Qi J, Deng H, Vivanco I, Mellinghoff IK, Jameison C, Sun R. Inhibition of the phosphatidylinositol 3-kinase-Akt pathway enhances gamma-2 herpesvirus lytic replication and facilitates reactivation from latency. J Gen VIrol. 2010;91(Pt 2):463-469.